evacetrapib   Click here for help

GtoPdb Ligand ID: 8401

Synonyms: LY2484595
Compound class: Synthetic organic
Comment: Evacetrapib is a cholesterylester transfer protein (CETP) inhibitor [1]. CETP was considered as a target for prevention of dyslipidemia and resucing cardiovascular mortality, with CETP inhibitors proposed as a direct route to raise HDL.
Clinical trial results for a number of CETP inhibitors have failed to show clinical benefit. Failed candidates include evacetrapib, anacetrapib, torcetrapib, and dalcetrapib [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 87.38
Molecular weight 638.28
XLogP 8.44
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC(=O)C1CCC(CC1)CN1CCCC(c2c1c(C)cc(c2)C)N(c1nnn(n1)C)Cc1cc(cc(c1)C(F)(F)F)C(F)(F)F
Isomeric SMILES OC(=O)C1CCC(CC1)CN1CCC[C@@H](c2c1c(C)cc(c2)C)N(c1nnn(n1)C)Cc1cc(cc(c1)C(F)(F)F)C(F)(F)F
InChI InChI=1S/C31H36F6N6O2/c1-18-11-19(2)27-25(12-18)26(5-4-10-42(27)16-20-6-8-22(9-7-20)28(44)45)43(29-38-40-41(3)39-29)17-21-13-23(30(32,33)34)15-24(14-21)31(35,36)37/h11-15,20,22,26H,4-10,16-17H2,1-3H3,(H,44,45)/t20?,22?,26-/m0/s1
InChI Key IHIUGIVXARLYHP-UXNJHFGPSA-N
No information available.
Summary of Clinical Use Click here for help
Evacetrapib was advanced to Phase 3 clinical evaluation, but development was discontinued due to lack of efficacy.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
CETP facilitates the transport of cholesteryl esters and triglycerides between the lipoproteins. Inhibition of this enzyme reduces LDL-cholesterol levels [2,4].